These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35840339)

  • 1. Disease activity of lung cancer at the time of acute exacerbation of interstitial lung disease during cytotoxic chemotherapy.
    Sekine A; Matama G; Hagiwara E; Tabata E; Ikeda S; Oda T; Okuda R; Kitamura H; Baba T; Satoh H; Misumi T; Komatsu S; Iwasawa T; Ogura T
    Thorac Cancer; 2022 Sep; 13(17):2443-2449. PubMed ID: 35840339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.
    Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A
    Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
    Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
    Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
    Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
    J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.
    Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
    Thorac Cancer; 2021 Jun; 12(11):1681-1689. PubMed ID: 33939332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.
    Nakao S; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
    Anticancer Res; 2019 Oct; 39(10):5725-5731. PubMed ID: 31570474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
    Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
    BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.
    Otsuka K; Nokihara H; Mitsuhashi A; Ozaki R; Yabuki Y; Yoneda H; Ogino H; Nishioka Y
    Thorac Cancer; 2022 Nov; 13(21):2978-2984. PubMed ID: 36106507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
    Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between acute exacerbation and progressive pulmonary fibrosis in interstitial lung disease: a retrospective cohort study.
    Zhai L; Wang Z; Yu W
    Ther Adv Respir Dis; 2024; 18():17534666241276800. PubMed ID: 39235441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glasgow Prognostic Score predicts chemotherapy-triggered acute exacerbation-interstitial lung disease in patients with non-small cell lung cancer.
    Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
    Thorac Cancer; 2021 Mar; 12(5):667-675. PubMed ID: 33480111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis.
    Izuka S; Yamashita H; Iba A; Takahashi Y; Kaneko H
    Rheumatology (Oxford); 2021 May; 60(5):2348-2354. PubMed ID: 33241299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.
    Nishiyama N; Honda T; Sema M; Kawahara T; Jin Y; Natsume I; Chiaki T; Yamashita T; Tsukada Y; Taki R; Miyashita Y; Saito K; Tateishi T; Sakashita H; Miyazaki Y
    Int J Clin Oncol; 2020 Feb; 25(2):282-291. PubMed ID: 31720993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of
    Akaike K; Saruwatari K; Oda S; Shiraishi S; Takahashi H; Hamada S; Iyama S; Horio Y; Tomita Y; Saeki S; Okamoto S; Ichiyasu H; Fujii K; Sakagami T
    Int J Clin Oncol; 2020 Apr; 25(4):681-690. PubMed ID: 31781994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy.
    Kobayashi H; Naito T; Omae K; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Endo M; Harada H; Takahashi T
    J Cancer; 2018; 9(11):2054-2060. PubMed ID: 29896291
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
    Kakiuchi S; Hanibuchi M; Tezuka T; Saijo A; Otsuka K; Sakaguchi S; Toyoda Y; Goto H; Kawano H; Azuma M; Ogushi F; Nishioka Y
    Respir Investig; 2017 Mar; 55(2):145-152. PubMed ID: 28274530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease.
    Hagiwara Y; Nakayama Y; Kudo S; Hayakawa T; Nakamura N; Kitamoto Y; Takahashi S; Tsujino K; Kubo N; Tamaki Y; Nagata Y;
    J Radiat Res; 2020 Jul; 61(4):563-574. PubMed ID: 32363376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.
    Okuda K; Hirose T; Oki Y; Murata Y; Kusumoto S; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Ohnishi T; Ohmori T
    Anticancer Res; 2012 Dec; 32(12):5475-80. PubMed ID: 23225454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation.
    Yamaguchi K; Iwamoto H; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Fujitaka K; Hamada H; Hattori N
    Respir Investig; 2022 Jul; 60(4):531-542. PubMed ID: 35504814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
    Lee JH; Jang JH; Park JH; Jang HJ; Park CS; Lee S; Kim SH; Kim JY; Kim HK
    PLoS One; 2021; 16(7):e0255365. PubMed ID: 34314462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.